Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs)

Main Article Content

Alexander Stratigos
Aleksandar Sekulic
Ketty Peris
Oliver Bechter
Martin Kaatz
Karl Lewis
Nicole Basset-Segiun
Anne Lynn Chang
Stephanie Dalle
Almudena Fernandez Orland
Lisa Licitra
Caroline Robert
Claas Ulrich
Axel Hauschild
Michael Migden
Reinhard Dummer
Siyu Li
Kosalai Mohan
Ebony Coates
Vladimir Jankovic
Nathalie Flaschi
Emmanuel Okoye
Ioannis Bassukas
Carmen Loquai
Vincent De Giorgi
Zeynep Eroglu
Ralf Gutzmer
Jens Ulrich
Susana Puig
Frank Seebach
Gavin Thurston
Israel Lowy
Timothy Bowler
Matthew Fury

Keywords

Locally Advanced Basal Cell Carcinoma, laBCC, Biologic, Cemiplimab, Hedgehog Inhibitor, HHI

Abstract

Abstract not available.

References

1. Sun Pharmaceuticals Industries, Inc. ODOMZO® (sonidegib) prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205266s004lbl.pdf. Revised September 2017. Accessed October 12, 2020.

2. Genentech, Inc. ERIVEDGETM (vismodegib) prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf. Revised January 2012. Accessed October 12, 2020.

3.Goodman AM et al. Oncoimmunology 2018;7:e1404217.

4. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

5. Migden MR et al. N Engl J Med. 2018;379:341–351.

6. Rischin D et al. J Immunother Cancer. 2020;8:e000775.

7. Regeneron Pharmaceuticals, Inc. LIBTAYO® [cemiplimab-rwlc] injection full US prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf. Accessed July 13, 2020.

8. Inman GJ et al. Nat Commun. 2018;9:3667.

Most read articles by the same author(s)

1 2 > >>